Malaria

The Lancet

Volumn 391, Issue 10130, 2018, Pages 1608-1621

  Ashley, Elizabeth A ^a,b   Pyae Phyo, Aung ^c,d   Woodrow, Charles J ^b,d  

^a Myanmar Oxford Clinical Research Unit   (Myanmar)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^d MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; IVERMECTIN; LEVAMISOLE; MALARIA VACCINE; MANNITOL; PYRIMETHAMINE PLUS SULFADOXINE; QUININE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ANOPHELES GAMBIAE; CASE MANAGEMENT; CHEMOPROPHYLAXIS; CLIMATE CHANGE; COMORBIDITY; DISEASE BURDEN; DISEASE ELIMINATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SAFETY; EXCHANGE BLOOD TRANSFUSION; FLUID RESUSCITATION; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MALARIA; MASS SCREENING; MIXED INFECTION; NONHUMAN; PATHOGENESIS; PILOT STUDY; PLASMODIUM; PLASMODIUM CYNOMOLGI; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM MALARIAE; PLASMODIUM OVALE; PLASMODIUM SIMIUM; PLASMODIUM VIVAX; POPULATION RESEARCH; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RECURRENT INFECTION; RELAPSE; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT FAILURE; VECTOR CONTROL; ANTIBIOTIC RESISTANCE; DISEASE ERADICATION; DRUG DEVELOPMENT; INSECTICIDE RESISTANCE; INSECTICIDE TREATED NET; MOSQUITO CONTROL; PROTECTION;

ANTIMALARIALS; ARTEMISININS; DISEASE ERADICATION; DRUG DISCOVERY; DRUG RESISTANCE, MICROBIAL; HUMANS; INSECTICIDE RESISTANCE; INSECTICIDE-TREATED BEDNETS; MALARIA; MALARIA VACCINES; MOSQUITO CONTROL; PROTECTIVE FACTORS; RISK FACTORS;

EID: 85045580319     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30324-6     Document Type: Review

References (140)

1. WHO. World malaria report 2017. 2017, World Health Organization, Geneva.
2. O'Brien, SF, Delage, G, Seed, CR, et al. The epidemiology of imported malaria and transfusion policy in 5 nonendemic countries. Transfus Med Rev 29 (2015), 162–171.
3. Abdullah, S, Karunamoorthi, K, Malaria and blood transfusion: major issues of blood safety in malaria-endemic countries and strategies for mitigating the risk of Plasmodium parasites. Parasitol Res 115 (2016), 35–47.
4. Caminade, C, Kovats, S, Rocklov, J, et al. Impact of climate change on global malaria distribution. Proc Natl Acad Sci USA 111 (2014), 3286–3291.
5. Nkumama, IN, O'Meara, WP, Osier, FH, Changes in malaria epidemiology in Africa and new challenges for elimination. Trends Parasitol 33 (2017), 128–140.
6. Snow, RW, Sartorius, B, Kyalo, D, et al. The prevalence of Plasmodium falciparum in sub-Saharan Africa since 1900. Nature 550 (2017), 515–518.
7. Singh, B, Kim Sung, L, Matusop, A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 363 (2004), 1017–1024.
8. Ta, TH, Hisam, S, Lanza, M, Jiram, AI, Ismail, N, Rubio, JM, First case of a naturally acquired human infection with Plasmodium cynomolgi. Mala J, 13, 2014, 68.
9. Brasil, P, Zalis, MG, de Pina-Costa, A, et al. Outbreak of human malaria caused by Plasmodium simium in the Atlantic Forest in Rio de Janeiro: a molecular epidemiological investigation. Lancet Glob Health 5 (2017), e1038–e1046.
10. Josling, GA, Llinas, M, Sexual development in Plasmodium parasites: knowing when it's time to commit. Nat Rev Microbiol 13 (2015), 573–587.
11. Bousema, T, Drakeley, C, Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 24 (2011), 377–410.
12. White, NJ, Malaria. Farrar, J, (eds.) Manson's tropical diseases, 23rd edn., 2013, Elsevier, London, 532–600.
13. Coatney, GR, Collins, WE, Warren, M, et al. CD-ROM. The primate malarias [original book published 1971]. 2003, Centers for Disease Control and Prevention, Atlanta.
14. Lennartz, F, Adams, Y, Bengtsson, A, et al. Structure-guided identification of a family of dual receptor-binding PfEMP1 that Is associated with cerebral malaria. Cell Host Microbe 21 (2017), 403–414.
15. Turner, L, Lavstsen, T, Berger, SS, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature 498 (2013), 502–505.
16. Fried, M, Duffy, PE, Malaria during pregnancy. Cold Spring Harb Perspect Med, 7, 2017, a025551.
17. Moore, KA, Simpson, JA, Wiladphaingern, J, et al. Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. BMC Med, 15, 2017, 117.
18. Buffet, PA, Safeukui, I, Deplaine, G, et al. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 117 (2011), 381–392.
19. Barber, BE, William, T, Grigg, MJ, et al. Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria. PLoS Pathog, 11, 2015, e1004558.
20. WHO. Severe malaria. Trop Med Int Health 19:suppl 1 (2014), 7–131.
21. Lalloo, DG, Shingadia, D, Bell, DJ, et al. UK malaria treatment guidelines 2016. J Infect 72 (2016), 635–649.
22. Taylor, WRJ, Hanson, J, Turner, GDH, White, NJ, Dondorp, AM, Respiratory manifestations of malaria. Chest 142 (2012), 492–505.
23. Herdman, MT, Sriboonvorakul, N, Leopold, SJ, et al. The role of previously unmeasured organic acids in the pathogenesis of severe malaria. Crit Care, 19, 2015, 317.
24. Maitland, K, Management of severe paediatric malaria in resource-limited settings. BMC Med, 13, 2015, 42.
25. Maude, RJ, Barkhof, F, Hassan, MU, et al. Magnetic resonance imaging of the brain in adults with severe falciparum malaria. Malar J, 13, 2014, 177.
26. Seydel, KB, Kampondeni, SD, Valim, C, et al. Brain swelling and death in children with cerebral malaria. N Engl J Med 372 (2015), 1126–1137.
27. Taylor, TE, Molyneux, ME, The pathogenesis of pediatric cerebral malaria: eye exams, autopsies, and neuroimaging. Annals NY Acad Sci 1342 (2015), 44–52.
28. Chiodini, PL, Malaria diagnostics: now and the future. Parasitology 141 (2014), 1873–1879.
29. Ndour, PA, Larreche, S, Mouri, O, et al. Measuring the Plasmodium falciparum HRP2 protein in blood from artesunate-treated malaria patients predicts post-artesunate delayed hemolysis. Science Transl Med, 9, 2017, eaaf9377.
30. Gamboa, D, Ho, MF, Bendezu, J, et al. A large proportion of P. falciparum isolates in the Amazon region of Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PLoS One, 5, 2010, e8091.
31. Berhane, A, Russom, M, Bahta, I, Hagos, F, Ghirmai, M, Uqubay, S, Rapid diagnostic tests failing to detect Plasmodium falciparum infections in Eritrea: an investigation of reported false negative RDT results. Malar J, 16, 2017, 105.
32. Luchavez, J, Baker, J, Alcantara, S, et al. Laboratory demonstration of a prozone-like effect in HRP2-detecting malaria rapid diagnostic tests: implications for clinical management. Malar J, 10, 2011, 286.
33. Mathison, BA, Pritt, BS, Update on malaria diagnostics and test utilization. J Clin Microbiol 55 (2017), 2009–2017.
34. Dondorp, A, Nosten, F, Stepniewska, K, Day, N, White, N, South East Asian Quinine Artesunate Malaria Trial group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366 (2005), 717–725.
35. Dondorp, AM, Fanello, CI, Hendriksen, IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 376 (2010), 1647–1657.
36. White, NJ, Looareesuwan, S, Warrell, DA, et al. Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 32 (1983), 1–5.
37. Esu, E, Effa, EE, Opie, ON, Uwaoma, A, Meremikwu, MM, Artemether for severe malaria. Cochrane Database Syst Rev, 9, 2014 CD010678.
38. Hanson, JP, Lam, SW, Mohanty, S, et al. Fluid resuscitation of adults with severe falciparum malaria: effects on acid-base status, renal function, and extravascular lung water. Crit Care Med 41 (2013), 972–981.
39. Maitland, K, Kiguli, S, Opoka, RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 364 (2011), 2483–2495.
40. Kiguli, S, Maitland, K, George, EC, et al. Anaemia and blood transfusion in African children presenting to hospital with severe febrile illness. BMC Med, 13, 2015, 21.
41. ISRCTN Registry. Transfusion and treatment of severe anaemia in African children trial registration ISRCTN84086586. https://doi.org/10.1186/ISRCTN84086586, 2013 (accessed Aug 20, 2017).
42. Crawley, J, Waruiru, C, Mithwani, S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 355 (2000), 701–706.
43. Maude, RJ, Hoque, G, Hasan, MU, et al. Timing of enteral feeding in cerebral malaria in resource-poor settings: a randomized trial. PLoS One, 6, 2011, e27273.
44. Takem, EN, Roca, A, Cunnington, A, The association between malaria and non-typhoid Salmonella bacteraemia in children in sub-Saharan Africa: a literature review. Malar J, 13, 2014, 400.
45. Worldwide Antimalarial Resistance Network Parasite Clearance Study Group. Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malar J, 14, 2015, 359.
46. White, NJ, Malaria parasite clearance. Malar J, 16, 2017, 88.
47. John, CC, Kutamba, E, Mugarura, K, Opoka, RO, Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti-infect Ther 8 (2010), 997–1008.
48. Maude, RJ, Silamut, K, Plewes, K, et al. Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. J Infect Dis 209 (2014), 120–129.
49. Tan, KR, Wiegand, RE, Arguin, PM, Exchange transfusion for severe malaria: evidence base and literature review. Clin Infect Dis 57 (2013), 923–928.
50. Val, F, Machado, K, Barbosa, L, et al. Respiratory complications of Plasmodium vivax malaria: systematic review and meta-analysis. Am J Trop Med Hyg 97 (2017), 733–743.
51. Rahimi, BA, Thakkinstian, A, White, NJ, Sirivichayakul, C, Dondorp, AM, Chokejindachai, W, Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J, 13, 2014, 481.
52. Anstey, NM, Douglas, NM, Poespoprodjo, JR, Price, RN, Plasmodium vivax: clinical spectrum, risk factors and pathogenesis. Adv Parasitol 80 (2012), 151–201.
53. Lampah, DA, Yeo, TW, Hardianto, SO, et al. Coma associated with microscopy-diagnosed Plasmodium vivax: a prospective study in Papua, Indonesia. PLoS Negl Trop Dis, 5, 2011, e1032.
54. Douglas, NM, Pontororing, GJ, Lampah, DA, et al. Mortality attributable to Plasmodium vivax malaria: a clinical audit from Papua, Indonesia. BMC Med, 12, 2014, 217.
55. Barber, BE, Grigg, MJ, William, T, Yeo, TW, Anstey, NM, The treatment of Plasmodium knowlesi malaria. Trends Parasitol 33 (2017), 242–253.
56. World Health Organization. Guidelines for the treatment of malaria. 3rd edn., 2015, WHO, Geneva.
57. Price, RN, von Seidlein, L, Valecha, N, Nosten, F, Baird, JK, White, NJ, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 14 (2014), 982–991.
58. WHO. World malaria report 2016. 2016, World Health Organization, Geneva.
59. Dellicour, S, Sevene, E, McGready, R, First-trimester artemisinin derivatives and quinine treatments and the risk of adverse pregnancy outcomes in Africa and Asia: a meta-analysis of observational studies. PLoS Med, 14, 2017, e1002290.
60. Pekyi, D, Ampromfi, AA, Tinto, H, et al. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med 374 (2016), 913–927.
61. Wilby, KJ, Ensom, MH, Pharmacokinetics of antimalarials in pregnancy: a systematic review. Clin Pharmacokinet 50 (2011), 705–723.
62. Chu, CS, White, NJ, Management of relapsing Plasmodium vivax malaria. Expert Rev Anti-infect Ther 14 (2016), 885–900.
63. Chu, CS, Bancone, G, Moore, KA, et al. Haemolysis in G6PD heterozygous females treated with primaquine for Plasmodium vivax malaria: a nested cohort in a trial of radical curative regimens. PLoS Med, 14, 2017, e1002224.
64. Marcsisin, SR, Reichard, G, Pybus, BS, Primaquine pharmacology in the context of CYP 2D6 pharmacogenomics: current state of the art. Pharmacol Ther 161 (2016), 1–10.
65. Llanos-Cuentas, A, Lacerda, MV, Rueangweerayut, R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet 383 (2014), 1049–1058.
66. Taylor, WR, White, NJ, Antimalarial drug toxicity: a review. Drug Saf 27 (2004), 25–61.
67. White, NJ, Why is it that antimalarial drug treatments do not always work?. Ann Trop Med Parasitol 92 (1998), 449–458.
68. WorldWide Antimalarial Resistance Network Lumefantrine PK/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med, 13, 2015, 227.
69. WorldWide Antimalarial Resistance Network DP Study Group. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data. PLoS Med, 10, 2013, e1001564.
70. Adjuik, MA, Allan, R, Anvikar, AR, et al. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med, 13, 2015, 66.
71. Nayyar, GM, Breman, JG, Newton, PN, Herrington, J, Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12 (2012), 488–496.
72. Douglas, NM, Nosten, F, Ashley, EA, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis 52 (2011), 612–620.
73. White, N, Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B, Biol Sci 354 (1999), 739–749.
74. Dondorp, AM, Nosten, F, Yi, P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361 (2009), 455–467.
75. Ashley, EA, Dhorda, M, Fairhurst, RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371 (2014), 411–423.
76. Menard, D, Khim, N, Beghain, J, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med 374 (2016), 2453–2464.
77. Amato, R, Lim, P, Miotto, O, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype–phenotype association study. Lancet Infect Dis 17 (2017), 164–173.
78. Witkowski, B, Duru, V, Khim, N, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 17 (2017), 174–183.
79. Ariey, F, Witkowski, B, Amaratunga, C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 505 (2014), 50–55.
80. Blasco, B, Leroy, D, Fidock, DA, Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nature Med 23 (2017), 917–928.
81. Phyo, AP, Ashley, EA, Anderson, TJC, et al. Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai–Myanmar Border (2003–2013): the role of parasite genetic factors. Clin Infect Dis 63 (2016), 784–791.
82. Thanh, NV, Thuy-Nhien, N, Tuyen, NT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J, 16, 2017, 27.
83. Imwong, M, Hien, TT, Thuy-Nhien, NT, Dondorp, AM, White, NJ, Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infect Dis 17 (2017), 1022–1023.
84. WorldWide Antimalarial Resistance Network. Tracking resistance to artemisinin collaboration II. http://www.wwarn.org/working-together/partner-projects/tracking-resistance-artemisinin-collaboration-ii, 2017 (accessed March 21, 2018).
85. White, NJ, Pukrittayakamee, S, Phyo, AP, et al. Spiroindolone KAE609 for falciparum and vivax malaria. NEngl J Med 371 (2014), 403–410.
86. McCarthy, JS, Lotharius, J, Ruckle, T, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis 17 (2017), 626–635.
87. White, NJ, Duong, TT, Uthaisin, C, et al. Antimalarial activity of KAF156 in falciparum and vivax malaria. N Engl J Med 375 (2016), 1152–1160.
88. Phyo, AP, Jittamala, P, Nosten, FH, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis 16 (2016), 61–69.
89. Wells, TN, Hooft van Huijsduijnen, R, Van Voorhis, WC, Malaria medicines: a glass half full?. Nature Rev Drug Discov 14 (2015), 424–442.
90. Phillips, MA, Burrows, JN, Manyando, C, van Huijsduijnen, RH, Van Voorhis, WC, Wells, TNC, Malaria. Nature Rev Dis Primers, 3, 2017, 17050.
91. Toure, OA, Valecha, N, Tshefu, AK, et al. A phase 3, double-blind, randomized study of arterolane maleate-piperaquine phosphate vs artemether-lumefantrine for falciparum malaria in adolescent and adult patients in Asia and Africa. Clin Infect Dis 62 (2016), 964–971.
92. Delves, MJ, Ruecker, A, Straschil, U, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother 57 (2013), 3268–3274.
93. Zoller, T, Junghanss, T, Kapaun, A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 17 (2011), 771–777.
94. Jauréguiberry, S, Ndour, PA, Roussel, C, et al., French Artesunate Working Group. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 124 (2014), 167–175.
95. Fanello, C, Onyamboko, M, Lee, SJ, et al. Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. BMC Infect Dis, 17, 2017, 575.
96. Rolling, T, Agbenyega, T, Krishna, S, Kremsner, PG, Cramer, JP, Delayed haemolysis after artesunate treatment of severe malaria – review of the literature and perspective. Trav Med Infect Dis 13 (2015), 143–149.
97. Olupot-Olupot, P, Engoru, C, Uyoga, S, et al. High frequency of blackwater fever among children presenting to hospital with severe febrile illnesses in eastern Uganda. Clin Infect Dis 64 (2017), 939–946.
98. Leoni, S, Buonfrate, D, Angheben, A, Gobbi, F, Bisoffi, Z, The hyper-reactive malarial splenomegaly: a systematic review of the literature. Malar J, 14, 2015, 185.
99. Langford, S, Douglas, NM, Lampah, DA, et al. Plasmodium malariae infection associated with a high burden of anemia: a hospital-based surveillance study. PLoS Negl Trop Dis, 9, 2015, e0004195.
100. Saadani Hassani, A, Marston, BJ, Impact of cotrimoxazole and insecticide-treated nets for malaria prevention on key outcomes among HIV-infected adults in low- and middle-income countries: a systematic review. J Acquire Immune Defic Syndr (1999) 68:suppl 3 (2015), S306–S317.
101. Hoglund, RM, Byakika-Kibwika, P, Lamorde, M, et al. Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications. Br J Clin Pharmacol 79 (2015), 636–649.
102. Kakuru, A, Achan, J, Muhindo, MK, et al. Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis 59 (2014), 446–453.
103. Galatas, B, Bassat, Q, Mayor, A, Malaria parasites in the asymptomatic: looking for the hay in the haystack. Trends Parasitol 32 (2016), 296–308.
104. Boyle, MJ, Reiling, L, Feng, G, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity 42 (2015), 580–590.
105. Van Braeckel-Budimir, N, Kurup, SP, Harty, JT, Regulatory issues in immunity to liver and blood-stage malaria. Curr Opin Immunol 42 (2016), 91–97.
106. Taylor, SM, Parobek, CM, Fairhurst, RM, Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 457–468.
107. Malaria Genomic Epidemiology Network. Reappraisal of known malaria resistance loci in a large multicenter study. Nat Genet 46 (2014), 1197–1204.
108. Leslie, T, Briceno, M, Mayan, I, et al. The impact of phenotypic and genotypic G6PD deficiency on risk of Plasmodium vivax infection: a case-control study amongst Afghan refugees in Pakistan. PLoS Med, 7, 2010, e1000283.
109. Louicharoen, C, Patin, E, Paul, R, et al. Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in southeast Asians. Science 326 (2009), 1546–1549.
110. Batchelor, JD, Malpede, BM, Omattage, NS, DeKoster, GT, Henzler-Wildman, KA, Tolia, NH, Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARC. PLoS Pathog, 10, 2014, e1003869.
111. Niangaly, A, Karthigayan, G, Amed, O, et al. Plasmodium vivax infections over 3 years in Duffy blood group negative Malians in Bandiagara, Mali. Am J Trop Med Hyg 97 (2017), 744–752.
112. Leffler, EM, Band, G, Busby, GBJ, et al. Resistance to malaria through structural variation of red blood cell invasion receptors. Science 356 (2017), 1140–1152.
113. Nevill, CG, Some, ES, Mung'ala, VO, et al. Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop Med Int Health 1 (1996), 139–146.
114. Radeva-Petrova, D, Kayentao, K, ter Kuile, FO, Sinclair, D, Garner, P, Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev, 10, 2014 CD000169.
115. Desai, M, Gutman, J, L'Lanziva, A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet 386 (2015), 2507–2519.
116. Madanitsa, M, Kalilani, L, Mwapasa, V, et al. Scheduled intermittent screening with rapid diagnostic tests and treatment with dihydroartemisinin-piperaquine versus intermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy in Malawi: an open-label randomized controlled trial. PLoS Med, 13, 2016, e1002124.
117. Cisse, B, Ba, EH, Sokhna, C, et al. Effectiveness of seasonal malaria chemoprevention in children under ten years of age in Senegal: a stepped-wedge cluster-randomised trial. PLoS Med, 13, 2016, e1002175.
118. Kolifarhood, G, Raeisi, A, Ranjbar, M, et al. Prophylactic efficacy of primaquine for preventing Plasmodium falciparum and Plasmodium vivax parasitaemia in travelers: a meta-analysis and systematic review. Trav Med Infect Dis 17 (2017), 5–18.
119. RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386 (2015), 31–45.
120. Neafsey, DE, Juraska, M, Bedford, T, et al. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N Engl J Med 373 (2015), 2025–2037.
121. Olotu, A, Fegan, G, Wambua, J, et al. Seven-year efficacy of RTS,S/AS01 malaria vaccine among young African children. Engl J Med 374 (2016), 2519–2529.
122. Sissoko, MS, Healy, SA, Katile, A, et al. Safety and efficacy of PfSPZ vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect Dis 17 (2017), 498–509.
123. Cowman, AF, Tonkin, CJ, Tham, WH, Duraisingh, MT, The molecular basis of erythrocyte invasion by malaria parasites. Cell Host Microbe 22 (2017), 232–245.
124. Crosnier, C, Bustamante, LY, Bartholdson, SJ, et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480 (2011), 534–537.
125. Fried, M, Duffy, PE, Designing a VAR2CSA-based vaccine to prevent placental malaria. Vaccine 33 (2015), 7483–7488.
126. Bustamante, LY, Powell, GT, Lin, YC, et al. Synergistic malaria vaccine combinations identified by systematic antigen screening. Proc Natl Acad Sci USA 114 (2017), 12045–12050.
127. WHO. Global plan for insecticide resistance management in malaria vectors (GPIRM). 2013, World Health Organization, Geneva.
128. Ranson, H, Lissenden, N, Insecticide resistance in African anopheles mosquitoes: a worsening situation that needs urgent action to maintain malaria control. Trends Parasitol 32 (2016), 187–196.
129. Strode, C, Donegan, S, Garner, P, Enayati, AA, Hemingway, J, The impact of pyrethroid resistance on the efficacy of insecticide-treated bed nets against African anopheline mosquitoes: systematic review and meta-analysis. PLoS Med, 11, 2014, e1001619.
130. World Health Organization Global Malaria Programme. Conditionsfor deployment of mosquito nets treated with pyrethroid and piperonyl butoxide. September 2017 (updated December 2017). http://www.who.int/malaria/publications/atoz/use-of-pbo-treated-llins/en/ (accessed March 21, 2018).
131. Wilson, AL, Chen-Hussey, V, Logan, JG, Lindsay, SW, Are topical insect repellents effective against malaria in endemic populations? A systematic review and meta-analysis. Malar J, 13, 2014, 446.
132. Sluydts, V, Durnez, L, Heng, S, et al. Efficacy of topical mosquito repellent (picaridin) plus long-lasting insecticidal nets versus long-lasting insecticidal nets alone for control of malaria: a cluster randomised controlled trial. Lancet Infect Dis 16 (2016), 1169–1177.
133. Alout, H, Foy, BD, Ivermectin: a complimentary weapon against the spread of malaria?. Expert Rev Anti Infect Ther 15 (2017), 231–240.
134. McLean, KJ, Jacobs-Lorena, M, Genetic control of malaria mosquitoes. Trends Parasitol 32 (2016), 174–176.
135. Marshall, JM, Taylor, CE, Malaria control with transgenic mosquitoes. PLoS Med, 6, 2009, e20.
136. Gantz, VM, Jasinskiene, N, Tatarenkova, O, et al. Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito Anopheles stephensi. Proc Natl Acad Sci USA 112 (2015), e6736–e6743.
137. Newby, G, Bennett, A, Larson, E, et al. The path to eradication: a progress report on the malaria-eliminating countries. Lancet 387 (2016), 1775–1784.
138. Landier, J, Kajeechiwa, L, Thwin, MM, et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of eastern Myanmar. Wellcome Open Res, 2, 2017, 81.
139. Imwong, M, Suwannasin, K, Kunasol, C, et al. The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infect Dis 17 (2017), 491–497.
140. Bennett, A, Bisanzio, D, Yukich, JO, et al. Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003–2015: a modelling study using data from national surveys. Lancet Glob Health 5 (2017), e418–e427.